FDA Commissioner Marty Makary resigned on Tuesday, May 7, 2026 [1], ending his tenure at the agency.
The departure of the head of the U.S. Food and Drug Administration comes during a period of significant internal instability and political friction. Because the FDA oversees the safety and efficacy of the nation's food and medicine supply, leadership volatility can impact regulatory consistency and public trust.
Makary led the agency for 13 months [1]. His resignation followed a period marked by controversy and reports that he had angered various political constituencies [1]. Other reports described the environment at the FDA headquarters in Washington, D.C., as one of general agency turmoil [2].
President Donald Trump addressed the situation after reports surfaced suggesting a plan to remove the commissioner. "I know nothing about the reported move to oust FDA chief Marty Makary amid agency turmoil," Trump said [3].
Following the resignation, Kyle Diamantas was named acting commissioner of the FDA [4]. Diamantas assumes leadership of the agency while the administration determines a permanent replacement.
The transition occurs as the agency navigates competing pressures from political stakeholders and internal staff. Makary's short term reflects the challenges of aligning medical regulatory standards with the political goals of the current administration, a tension that contributed to the turmoil preceding his exit [5].
“Marty Makary resigned Tuesday after leading the agency for just 13 months.”
The rapid departure of Marty Makary suggests a disconnect between the FDA's regulatory leadership and the political expectations of the Trump administration. With an acting commissioner now in place, the agency faces a period of uncertainty that may slow the implementation of long-term policy shifts in food and drug oversight.
